Log In
Print
BCIQ
Print
Print this Print this
 

bertilimumab (CAT-213, iCo-008)

  Manage Alerts
Collapse Summary General Information
Company iCo Therapeutics Inc.
DescriptionHuman mAb against eotaxin-1
Molecular Target Chemokine CC motif ligand 11 (CCL11)
Mechanism of ActionEotaxin-1 inhibitor
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$33.0M

$1.0M

$32.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today